Prostate cancer radiation device poised for commercialisation in United States

Radiadyne of Houston Texas launched at this year’s American Society for Therapeutic Radiology and Oncology (ASTRO) in Chicago a technologically advanced ‘Prostate Immobilizer Balloon System’ which supports adaptive radiation therapy for prostate cancer patients.

This new device to aid in cancer treatment incorporates sensors developed by researchers at the University of Wollongong’s Centre for Medical Radiation Physics (CMRP), under the directorship of Professor Anatoly Rozenfeld.

“The Moskin Dosimetry Sensor Technology, which has been under development at the CMRP for some years, detects and will measure in real-time the radiation exposure immediately adjacent to the rectal wall when a patient is undergoing treatment for prostate cancer.

“By doing this, we aim to help support the accurate radiation dosage requirements for the patient. Adaptive Radiation Therapy assists in the protection of the rectal wall which is an area that can be susceptible to radiation exposure causing complications,” according to UOW Manager for Innovation and Commercialisation, Mr Tony Enright.

The intellectual property of the University of Wollongong has been registered for international patent protection and has been licensed exclusively to Radiadyne for use with its Prostate Immobilizer System.

The Radiadyne Prostate Immobilizer Balloon system with Moskin sensor will be available for commercial sales in the United States pending regulatory clearance from the Food and Drug Administration (FDA).

For more information on Radiadyne see their website information at http://www.radiadyne.com

Media seeking more information should call Tony Enright at the University of Wollongong on (02) 4221 4129 email tony_enright@uow.edu.au

Last reviewed: 3 November, 2009